NEW YORK (GenomeWeb News) – Private equity firm Arsenal Capital Partners today announced it has bought Certara, a provider of model-based drug development and data analytics software and consulting services to the biopharmaceutical research and development market.

Arsenal bought Certara from Vector Capital, which backed Jim Hopkins in forming Certara in 2007. Hopkins is now Certara's CEO.

The financial details of the acquisition were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease. 

Jun
23
Sponsored by
PerkinElmer

This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.